Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 10/20 | 0.37 |
| ▸ | PTPRC | P08575 | 1/20 | 0.37 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | PTPRB | P23467 | 1/20 | 0.37 |
| ▸ | PTPRE | P23469 | 1/20 | 0.37 |
| ▸ | ANO1 | Q5XXA6 | 5/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 4/20 | 0.32 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.32 |
| ▸ | RAB7A | P51149 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5456259 | 0.82 | CFTR (0.47) | CFTRCNR2PTPRCPTPN2PTPN1 | |
| SCHEMBL5448258 | 0.80 | CFTR (0.42) | CFTRCNR2PTPRCPTPN2PTPN1 | |
| SCHEMBL5448493 | 0.76 | CFTR (0.45) | CFTRCNR2PTPRCPTPN2PTPN1 | |
| SCHEMBL5447424 | 0.76 | CFTR (0.46) | CFTRCNR2PTPRCPTPN2PTPN1 | |
| SCHEMBL5458312 | 0.76 | CFTR (0.57) | CFTRCNR2PTPRCPTPN2PTPN1 | |
| SCHEMBL5456402 | 0.73 | CFTR (0.43) | CFTRCNR2PTPRCPTPN2PTPN1 | |
| SCHEMBL5460332 | 0.71 | CFTR (0.46) | CFTRCNR2PTPRCPTPN2PTPN1 | |
| SCHEMBL5467477 | 0.69 | CFTR (0.60) | CFTRCNR2PTPRCPTPN2PTPN1 | |
| SCHEMBL5455685 | 0.69 | CFTR (0.63) | CFTRCNR2PTPRCPTPN2PTPN1 | |
| SCHEMBL5455938 | 0.68 | CNR2 (0.69) | CFTRCNR2PTPRCPTPN2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | claimed |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | TBCA, PARK7, NFATC1 | CFTR 2030/4885CNR2 2272/4885PTPRC 1457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.